Berenberg initiates coverage on Recro Pharma (NASDAQ: REPH) with a Buy rating and a price target of $21.25.Analyst Patrick Trucchio ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE